About us

  • WHO WE ARE

Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy

Our breakthrough technology aims to transform outcomes by directly addressing the genetic root causes of disease.

Welcome to AlveoGene, an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy .

Enabled by our proprietary InGenuiTy® platform, our approach aims to address the genetic causes of serious respiratory diseases – delivering optimal therapy directly to the site of action in the lungs.

At AlveoGene, we’re driven by the vision of a future where patients can breathe freely and live life to the fullest.

Join us in our mission to empower patients and families, as we work tirelessly to create a world where rare respiratory diseases are no longer a barrier to vibrant living.

Contact Us
  • Company History

AlveoGene has been created by Oxford Science Enterprises (OSE), Harrington Discovery Institute at University Hospitals (Harrington), and Old College Capital (OCC), the University of Edinburgh’s venture investment fund, in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC).

The GTC was founded in 2001 to catalyse the application of pioneering research to gene therapy development and manufacturing related to cystic fibrosis and other respiratory diseases, and originated at Imperial College London and the Universities of Oxford and Edinburgh.

AlveoGene has secured an exclusive licence to a proprietary and validated next-generation lentiviral delivery platform (InGenuiTy™) developed by the GTC for the treatment of respiratory diseases with high unmet need (excluding the use of the CFTR gene which is mutated in cystic fibrosis).

Gene therapies developed using the InGenuiTy™ platform can be delivered through a nebuliser, transducing lung epithelial cells with high efficiency and producing a long duration of action. Importantly, these effects can be achieved following repeated administration.

The platform has been developed over more than a decade, supported by approximately £72 million in grant funding, including from the Wellcome Trust, Department of Health and Social Care,  Medical Research Council and the Cystic Fibrosis Trust.

  • About the GTC

The UK Respiratory Gene Therapy Consortium (GTC) was created in 2001 by leading clinicians and academics from Imperial College London and the Universities of Oxford and Edinburgh who have worked together for more than 20 years with a focus on translating gene therapy for respiratory diseases.

The GTC has undertaken six non-viral Phase 1/2a proof-of-concept studies and the first Phase 2b gene therapy trial for Cystic Fibrosis, which met its primary outcome.

In parallel, it has developed the novel lentiviral vector, which underpins AlveoGene’s InGenuiTy® platform and which is relevant to both CF (licensed to Boehringer Ingelheim and now in clinical trials) and multiple other lung conditions.

The Strategy Group that oversees the GTC are all co-founders of AlveoGene, and include Professor Eric Alton (Imperial College), Dr Chris Boyd (University of Edinburgh), Professor Deborah Gill (Oxford University), Professor Uta Griesenbach (Imperial College), Professor Steve Hyde (Oxford University) and Dr Gerry McLachlan (University of Edinburgh).

Further details and commentary can be found at www.respiratorygenetherapy.org.uk/